Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2024 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors

First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune systemsInvestigational package of broad immune agonists derived from Gram-negative bacteria...